Pfizer misses revenue expectations for Q1

Quote

anonymous

Guest
Pfizer posted a 1% improvement in revenues of $12.9 billion for the first quarter of 2018. Reported net income jumped 14% to $3.5 billion, while adjusted net income grew 11% to $4.6 billion. Reported EPS rose 15% to $0.59, while adjusted EPS grew 12% to $0.77 compared to last year. While revenue fell short of Wall Street expectations, net income for the quarter topped the consensus. https://news.alphastreet.com/pfizer-1q-2018-earnings/
 




all you need to know is that PFE stock hasn’t hit a new high in 18 years during one of the greatest bull runs of all time....way to go Management you could probably mess up a wet dream...
 








please, nobody worry or panic.

Pfizer has been facing massive revenue from operations for years due to parent expirations.

The impact of these losses has been partially offset over the years by non-operating revenues.

My guess is that Pfizer is done with using creative accounting to hit our numbers and that is a good thing. The focus is on returning to growth due to operations over the next 2-3 years.

If this is the case, it will be nice to see the stock price settle in at very realistic levels ahead of the beginning of operational growth.
 
























Top Bottom
Back
Quote